Phase 1, randomized, placebo controlled, double blind, single dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.
Completed
- Conditions
- AnthraxBacillus anthracis10004018
- Registration Number
- NL-OMON36585
- Lead Sponsor
- IQ Therapeutics
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
Male and female subjects, aged between 18 and 55, BMI 18 to 30 kg/m2
Exclusion Criteria
Clinical significant abnormalities during medical research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To investigate the safety and tolerability of the intravenously applied<br /><br>(directly given into a blood vessel) new test compound.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- To study how the test compound is absorbed, broken-down and excreted by the<br /><br>body.<br /><br>- To study the effect of new test compound on the body.</p><br>